Literature DB >> 3600916

Steroid-responsive relapsing nephrotic syndrome associated with early diabetic glomerulopathy in a child.

R Peces, J R Riera, C López Larrea, J Alvarez.   

Abstract

A child developed steroid-responsive nephrotic syndrome at the age of 3 years. 6 years later, he developed insulin-dependent diabetes mellitus. At this time renal biopsy disclosed minimal-change disease. After multiple relapses requiring cyclophosphamide or repeated courses of steroid therapy, a second renal biopsy, 5 years after the first, revealed early diabetic changes with associated exudative lesions. The nephrotic syndrome remains responsive to steroids and cyclophosphamide, and the patient maintains an increased glomerular filtration rate and normal blood pressure 3.5 years afterwards. His HLA typing showed DR4 and DR7. Since DR4 and DR7 are associated with diabetes and minimal-change disease, respectively, we speculate that he could carry the genetic predisposition for the development of both diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3600916     DOI: 10.1159/000184310

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

1.  Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  J Brodehl; M Brandis; U Helmchen; P F Hoyer; R Burghard; J H Ehrich; R B Zimmerhackl; W Klein; K Wonigeit
Journal:  Klin Wochenschr       Date:  1988-11-15

2.  Simultaneous onset of steroid resistant nephrotic syndrome and IDDM in two young children.

Authors:  Jameela A Kari; Sherif M El-Desoky; Ghadeer Mokhtar; Sawsan M Jalalah
Journal:  BMJ Case Rep       Date:  2010-11-29

3.  Concurrent minimal change nephrotic syndrome and type 1 diabetes mellitus in an adult Japanese woman: a case report.

Authors:  Ryuzoh Nishizono; Hiroki Kogou; Yuri Ishizaki; Akihiro Minakawa; Masao Kikuchi; Hiroko Inagaki; Yuji Sato; Shouichi Fujimoto
Journal:  BMC Nephrol       Date:  2020-09-23       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.